Abstract
British Journal of PharmacologyVolume 178, Issue 10 p. 2161-2161 CORRECTIONFree Access Correction First published: 01 May 2021 https://doi.org/10.1111/bph.15449AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the paper “The anti-parasitic drug miltefosine suppresses human eosinophil activation and ameliorates murine allergic inflammation in vivo” by Knuplez et al, the title has been amended to “The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice.” REFERENCE Knuplez, E., Kienzl, M., Trakaki, A., Schicho, R., Heinemann, A., Sturm, E. M., & Marsche, G. (2021). The anti-parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice. British Journal of Pharmacology, 178, 1234– 1248. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume178, Issue10Themed Issue: Cellular metabolism and diseasesMay 2021Pages 2161-2161 ReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
